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Abstract
Purpose—The purpose of this review is to highlight recent data regarding the impact of
exposure to tobacco smoke on influenza virus infection. This is timely because of the continuing
pattern for influenza to cause epidemics and pandemics.
Recent findings—Experimental animal studies suggest that tobacco smoke severity of
respiratory disease with influenza. The interaction is complex and dependent on dose and
chronicity of both virus and smoke exposure. Smoke-induced oxidant stress and suppression of
innate immunity are mechanistic factors leading to worse disease. Experiments using human
respiratory cells show that tobacco smoke increases viral replication through mechanisms
including suppression of antiviral pathways and altered cytokine patterns in cell types with central
roles in mucosal innate immunity, such as epithelium, dendritic cells and natural killer cells.
Studies also suggest a role for antioxidant strategies in reducing risk. Human volunteer studies
using live attenuated influenza virus as a model appear to corroborate many of these findings.
Summary—Exposure to tobacco smoke remains extremely prevalent worldwide. While
avoidance of exposure is a primary goal, it is important to understand the mechanisms underlying
increased infection risk with tobacco smoke and other pollutant exposures, so that novel
preventive or treatment strategies can be developed.
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Influenza virus is a common human respiratory pathogen resulting in annual epidemics and
periodic pandemics due to antigenic shift, such as the most recent one in 2009 [1].
Individuals with chronic respiratory and other diseases are at high risk for complications
from influenza, but the potential for catastrophic events like the 1918 pandemic makes it
important to mitigate risk factors relevant even to healthy populations. The purpose of this
brief review is to highlight recent data from our laboratory and others, regarding the impact
of exposure to tobacco smoke on influenza infection.
EPIDEMIOLOGY
Exposures to environmental pollutants such as cigarette smoke have been associated with
increased susceptibility to influenza infections. Epidemiological studies in the past have
shown that smokers are more susceptible to influenza virus infections than non-smokers
[2,3], but the mechanisms mediating this effect are not clear. In a 16-year mortality follow-
up of nearly 300,000 US veterans, influenza-related mortality (pneumonia and influenza
deaths combined) was higher in cigarette smokers than in nonsmokers [4]. A cohort study of
female military recruits showed that smoking was a risk factor for severe influenza-like
illness during an outbreak of influenza A (H1N1) subtype infection [3]. Similarly, an
influenza outbreak in the Israeli army demonstrated that smokers were more susceptible to
influenza virus infections than nonsmokers, although influenza-specific antibody levels were
not decreased [3,5,6]. A recent retrospective study based on Thailand’s National Avian
Influenza Surveillance system showed an increased risk of fatal influenza outcomes in
current smokers [7]. To summarize, cohort studies indicate that smoking increases
susceptibility and severity of influenza infection, and available evidence suggests that the
effects of cigarette smoke on susceptibility to influenza infection may involve elements of
early or innate host defense against viruses. However, the mechanisms underlying this
observation have remained unclear.
EXPERIMENTAL ANIMAL MODELS
In mice, chronic exposure to mainstream cigarette smoke can alter influenza virus-induced
primary antiviral and inflammatory responses, but adaptive immune responses, as marked by
influenza-specific antibody production, appear to be unaffected. Exposure of C57BL/6 mice
for 3-5 months to mainstream tobacco smoke caused suppression of inflammatory responses
to low-dose influenza in BALF (neutrophils, mononuclear cells) but no change for levels of
cytokines IL-6, TNF-α, or MIP-2 [8]. In contrast, in the case of high-dose influenza, smoke
exposure was associated with heightened IL-6 and TNF-α responses. These experiments
suggest that the effect of tobacco smoke on host response to influenza is complex and partly
dependent on chronicity of exposure and on infection dose. Alveolar macrophages from
chronically smoke-exposed mice had reduced LPS-stimulated cytokine production (IL-6,
TNF-α, RANTES) as well as reduced nuclear translocation of NF-κB and AP-1 [9]. In
another study, mice were exposed to cigarette smoke and then infected with influenza A by
intranasal infection. Cigarette smoke exposure inhibited lung T-cell production of IFN-γ
during infection with influenza A virus via decreased phosphorylation of transcription
factors, and resulted in increased weight loss and mortality [10]. The Nrf2-mediated
antioxidant system is essential to protect the lungs from oxidative injury and inflammation.
Yageta et al. [11] investigated the role of Nrf2 in protection against influenza virus-induced
pulmonary inflammation after cigarette smoke exposure and found induction of antioxidant
genes in lungs of wild-type mice but not those of Nrf2-deficient mice after cigarette smoke
exposure. Cigarette smoke-exposed Nrf2-deficient mice showed higher rates of mortality
than did wild-type mice after infection, with enhanced peribronchial inflammation, lung
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permeability damage, and mucus hypersecretion. Lung oxidant levels and NF-κB-mediated
inflammatory gene expression in the lungs were also enhanced in Nrf2-deficient mice,
indicating that Nrf2-dependent antioxidant pathways are pivotal for protection against
influenza-induced pulmonary inflammation and injury under oxidative conditions.
In summary, experimental animal studies suggest that exposure to tobacco smoke increases
risk of severe respiratory disease with influenza. The interaction is complex and dependent
on dose and chronicity of both virus and smoke exposure. Smoke-induced oxidant stress and
suppression of innate (but not acquired) immunity are mechanistic factors leading to risk of
worse disease.
EXPERIMENTAL STUDIES WITH HUMAN CELLS IN VITRO
The respiratory epithelium is the main target of respiratory viruses and plays an important
role during the initial antiviral defense responses. Viral infection normally induces the
production of type I interferons (IFN), which in turn activate the synthesis of interferon-
stimulated genes (ISGs) and as a consequence limit viral replication [12]. Some
experimental studies of the impact of tobacco smoke and oxidant pollutants on human
respiratory epithelium in vitro have found a stimulatory effect on inflammatory cytokine
production [13-18]. However, it is possible that the predominant early producers of IL-6 in
respiratory mucosae are resident non-epithelial innate host defense cells. There is evidence
in both animal models and human studies for cigarette smoke-induced suppression of some
functions of these cell types [8,19-21]. A common pathophysiologic effect of many tobacco
smoke components may be to increase cellular oxidant stress, which can alter host defense
and virus clearance [22]. Beyond direct effects of tobacco smoke, it is possible that
inflammatory responsiveness to subsequent microbial stimuli could be suppressed after prior
smoke exposure. Kulkarni et al. [23] recently reported that cigarette smoke extract
suppressed IL-8 and IL-6 responses of human and murine respiratory epithelial cells after
bacterial stimulation, an effect that was abrogated by antioxidants.
Recent in vitro data from our laboratory suggest that tobacco smoke directly inhibits
epithelial antiviral pathways. Nasal epithelium in long term differentiated cell culture from
smokers responded to influenza infection with greater cytotoxicity, IL-6 release, and viral
shedding than cells from non-smokers, effects associated with increased DNA methylation
of the interferon regulatory factor 7 (IRF7) gene, a key transcriptional factor in the context
of a viral infection [16]. Previous studies demonstrated that hypermethylation of IRF7
results in decreased ability of type I IFNs to induce gene expression [24]. IRF7 induction
after influenza was suppressed both in vitro in long-term differentiated cultures of nasal
epithelium, and in freshly biopsied nasal epithelial cells obtained from smokers after
inoculation with LAIV [16] (Figure 1). Expression of IRF7 is critical for amplification of the
type I interferon response [25]. Thus, it is conceivable that suppressed epithelial type I IFN
signaling contributes to enhanced viral replication in smokers and second-hand smoke
(SHS)-exposed individuals. Interestingly, our observations appear to be in contrast to a
previous study which demonstrated that mice exposed to cigarette smoke for 2 weeks and
subsequently stimulated with poly I:C had increased levels of type I IFNs in bronchoalveolar
lavage fluid [26]. Similarly, airway epithelial cells exposed to cigarette smoke condensate
and infected with RSV showed greater expression of IRF7 [27].
We also established a model using differentiated nasal epithelial cells (NEC) from
nonsmokers and smokers, co-cultured with peripheral blood monocyte-derived dendritic
cells (mono-DC) from nonsmokers [28]. We observed that both NEC and mono-DC co-
cultured with NEC from smokers exhibited suppressed IRF-7, Toll-like receptor-3, and
retinoic acid inducible gene-1 (Figure 2), likely because of suppressed NEC production of
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IFNα. Furthermore, NEC/mono-DC co-cultures using NEC from smokers exhibited
suppressed concentrations of the T-cell/natural killer (NK) cell chemokine interferon
gamma-induced protein 10 (IP-10) after infection with influenza. In contrast, NEC/mono-
DC co-cultures using NEC from smokers contained increased influenza-induced
concentrations of the Th2 chemokines thymic stromal lymphopoeitin (TSLP) and thymus
and activation-regulated chemokine (TARC). Thus, in this model, in the context of influenza
infection smokers’ NEC create an overall cytokine microenvironment that suppresses the
interferon-mediated Th1 response and enhances the TSLP-TARC-mediated Th2 response,
with the potential to modify underlying susceptibilities to respiratory viral infections, and
the likelihood of acquiring allergic diseases.
Wu et al. [29], using a human lung organ culture model, found that 2-20% cigarette smoke
extract (CSE) inhibited influenza-induced IP-10 protein and mRNA expression, IFN-β
mRNA, and RIG-I mRNA and protein expression. Inhibition of viral-mediated RIG-I
induction by CSE was prevented by the antioxidants N-acetyl-cysteine and glutathione. We
also have observed that the induction of Nrf2 via the antioxidants sulforaphane and
epigallocatechin gallate (EGCG) inhibits viral entry and replication in cultured respiratory
epithelium, and increased expression of RIG-I, IFN-β, and MxA at baseline in the absence
of infection [30].
In summary, experiments using human respiratory cells (epithelial and other relevant cell
types) in vitro generally show that tobacco smoke increases viral replication. Many studies,
including our own using human nasal epithelial cells, show that tobacco smoke suppresses
antiviral pathways; this may be linked to epigenetic modification of key transcription factors
and may be mitigated by antioxidants. Like in animal models, effects of smoke exposure on
specific pathways in vitro are somewhat model-specific, and our co-culture data demonstrate
the potential importance of interactions between epithelial and other mucosal cell types with
central roles in innate immunity, such as DC and NK cells.
STUDIES IN HUMAN VOLUNTEERS
Given the model-specific variability and complexity noted above, we sought to develop a
protocol for the study of human airway responses to virus in the intact human respiratory
tract. Nasal delivery of live attenuated influenza virus (LAIV) vaccine results in transient
viral shedding and induces the full range of host immune responses similar to a natural
influenza infection without inducing serious adverse effects [31-34] and therefore is a
potentially useful tool to study influenza infections in humans in vivo. To test how cigarette
smoke exposure alters inflammatory and antiviral responses to influenza in the intact human
respiratory tract, we serially sampled nasal secretions in an observational cohort study
comparing local nasal mucosal responses to LAIV among healthy young adults who are
active smokers, nonsmokers exposed to secondhand smoke, and unexposed controls [35].
This was an observational cohort study comparing nasal mucosal responses to LAIV among
young adult active smokers (n=17), nonsmokers exposed to secondhand smoke (SHS,
n=20), and unexposed controls (n=23). Virus RNA and inflammatory factors were measured
in nasal lavage fluids (NLF) serially after LAIV inoculation. The time course of rise and
decline of mediators in NLF after LAIV inoculation in normal volunteers is shown in Figure
3. For key endpoints, peak and total (area under curve) responses were compared among
groups. Compared with controls, NLF IL-6 responses to LAIV (peak and total expressed as
area under curve) were suppressed in smokers (Figure 4A). There were significant
associations between urine cotinine and NLF IL-6 responses (negative correlation) or virus
RNA in NLF cells (positive correlation) for all subjects combined. Virus RNA in NLF cells
was significantly increased in smokers (Figure 4B), as were IP-10/virus ratios.
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While it is also possible that smokers shed more viral sequences for reasons unrelated to
innate immunity (e.g. altered mucociliary clearance), we hypothesize that increased
replication is the mechanism here due to the extended time course for increased virus in
smokers and our in vitro experience in which replication is enhanced [16]. In general our
study’s results thus seem to most closely correlate with the inflammatory suppression effects
associated with chronic smoke exposure and “low dose” virus in murine models described
above. In the context of influenza infections, IL-6 is a key cytokine important for regulating
the shift from innate to adaptive components of the antiviral immune responses [36]
including proliferation of T cells and influenza-specific T memory cells [37]. Therefore,
suppressed induction of IL-6 expression after infection with influenza could have an impact
on T cell-dependent adaptive immune responses, though we did not measure T cell
responses in the present study. There was also evidence that IFNγ is suppressed in smokers.
Nonsmokers exposed regularly to SHS also had suppressed total IL-6 responses after LAIV,
and generally appeared to have results which were intermediate between controls and active
smokers. Along with a statistically significant correlation between urine cotinine levels and
virus quantity, this suggests that the factor(s) responsible for these changes are present in
SHS as well as in mainstream cigarette smoke. This observational cohort study thus suggests
that either active or second hand exposures to tobacco smoke may have a measureable
impact on early innate respiratory mucosal host defense responses to influenza virus.
In a subsequent observational cohort study, we used a similar protocol to characterize non-
epithelial immune cells in NLF after LAIV, using flow cytometry [38]. We observed that
NK cells were present in NLF and constituted a significant portion of NLF immune cells.
NK cell activation during influenza infection is dependent upon secretion of cytokines and
chemokines such as RANTES and IP-10 from cells in the respiratory mucosa [39,40]
through binding to chemokine receptors CCR5 and CXCR3, respectively. Upon activation
by pathogens and inflammatory mediators such as Type I IFNs, IL-12, and IL-15, NK cells
can become more cytotoxic as they reduce CD56 expression and acquire CD16 expression
[41]. In our study, cytotoxic (CD56+CD16+) NK cells, which release granules containing
perforin and granzymes to induce apoptosis in influenza infected cells [42], increased in
normal volunteers after LAIV, but these responses were significantly suppressed in smokers
(Figure 5). Peripheral blood NK cell activation was unaffected by smoking status. Thus a
further mechanism for increased susceptibility of smokers to influenza may be suppression
of the normal activation of mucosal cytotoxic NK cells after infection.
SUMMARY AND CONCLUSIONS
As pointed out by van Zyl-Smit et al. [43], at the beginning of the 21st century, we are
facing the convergence of several epidemics including tobacco smoking and influenza, and
these epidemics interact by way of increasing disease susceptibility and worsening
outcomes. Smoking and exposure to second hand tobacco smoke remain extremely
prevalent worldwide, and their effects on susceptibility to infection could be shared by other
common oxidant particulate pollutants such as biomass burning or diesel exhaust. Exposure
to all of these factors is likely to increase with increasing global urbanization. It is therefore
important that we begin to understand the mechanisms underlying increased infection risk
with tobacco smoke exposure. Data from recent experimental studies point toward
suppression by tobacco smoke of several specific antiviral and innate host defense pathways,
both epithelial and non-epithelial, at the level of the respiratory mucosa. Studies also suggest
a possible role for antioxidant strategies in reducing risk. Further investigation of these
mechanisms is warranted due to their far-reaching implications for human health.
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1. Exposure to tobacco smoke remains very common, and epidemiologic data
indicate that this exposure increases risk for influenza and other respiratory virus
infections.
2. Recent experimental data in animal models and in human cell culture suggest
that tobacco smoke components can inhibit antiviral pathways and increase
susceptibility to influenza, via mechanisms involving oxidant stress.
3. Recent data from studies in human volunteers inoculated with live attenuated
influenza virus appear consistent with many of these findings.
4. Additional studies are needed investigating whether antioxidant strategies can
enhance innate immunity to influenza and other respiratory viral infections, in
populations exposed to air pollutants.
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Expression of IRF7 in NECs from smokers and nonsmokers. The NECs were infected with
influenza A Bangkok/2/79 or left uninfected, and analyzed for IRF7 expression 24 hours
after infection. (A) Total RNA was analyzed for IRF7 mRNA and normalized to β-actin
mRNA concentrations (n = 16 smokers; n = 14 nonsmokers). (B) Whole cell lysates were
analyzed for IRF7 and IRF3 protein levels by Western blotting. Membranes were stripped
and analyzed for β-actin to assure equal loading. Representative immunoblots are shown.
(C) Densitometric analysis of IRF7 protein levels (n = 6 smokers; n = 6 nonsmokers).
*Significantly different from noninfected cells (P < 0.05). # Significantly different from
smokers (P < 0.05). Previously published in reference [16].
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Total RNA from nonsmoker and smoker NEC/mono-DC co-cultures was collected 24 h post
influenza infection. qRT-PCR (normalized to β-actin and expressed as fold induction over
non-infected control) was performed for (A) IP-10 in NEC, (B) IP-10 in mono-DC, (C)
RANTES inNEC, and (D) RANTES in mono-DC. Data are expressed as mean ± SEM.
Nonsmoker n=5, smoker n=5. #p<0.05, ##p<0.01, ###p<0.001 vs non-infected control,
*p<0.05, ***p<0.001 for nonsmoker vs. smoker. Previously published in reference [28].
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Time course of influenza virus measured by qRT-PCR as ratio of influenza type B HA RNA
to β-actin mRNA in NLF cells and cytokines in NLF, after inoculation with LAIV in healthy
nonsmoking subjects (controls). Cytokine data are shown as fold change (△) from day 0
baseline, to illustrate differential responses among the cytokines. All data points are shown
as median for study day. IP-10, IL-6, and IFNγ but not other cytokines showed statistically
significant increases (days 2-4) compared with day 0. Previously published in reference
[35].
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(A) Mixed-effects model curves for influenza B virus quantity (hemagglutinin RNA
normalized to β-actin RNA) and (B) for IL-6 in NLF from Controls (blue circles and solid
line), SHS-exposed nonsmokers (red circles and broken line), and active Smokers (black
circles and dotted line). In the linear mixed model fitting, the response variable is the log-
transformed fold change from the baseline. Covariates include time, time2, group and their
interactions. Not previously published.
Noah et al. Page 13














Cytotoxic NK cell percentages and activity were analyzed in NLF of nonsmokers and
smokers after LAIV inoculation. A) CD56+CD16+ cytotoxic NK cell percentages of total
NK cells were decreased in the NLF of smokers following LAIV. Kruskal-Wallis p=0.09,
*p<0.05 nonsmoker vs smoker posttest. Nonsmokers n=12 (■, solid line), smokers n=9 (▲,
dashed line). B) Granzyme B activity was decreased in NLF of smokers following LAIV
inoculation. Kruskal-Wallis p<0.01, *p<0.05 nonsmoker vs smoker posttest. Nonsmokers
n=13 (■, solid line), smokers n=13 (▲, dashed line). Previously published in reference [38].
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